Records lung cancer patients' diagnosis and treatment in Algeria
Collects routine data on adults with lung cancer across 21 Algerian hospitals.
Plain-language title generated from the registry record
Registry title: ALG-LungCancerRegistry (SAFRO2202)
Key facts
- Where
- Algiers, Annaba, Batna City, Béjaïa, Blida, Constantine, El Oued, Laghouat, Oran, Ouargla, Sétif, Sidi Bel Abbes, Tipasa, and Tizi Ouzou, AlgeriaSee the 20 sites
Where in Algeria
- Centre Pierre et Marie CurieAlgiers, AlgeriaTaking people
- Chu Beni Messous - Isaad HassaniAlgiers, AlgeriaTaking people
- CHU Mohamed Lamine Debaghine - Bab-el-OuedAlgiers, AlgeriaTaking people
- EPH RouibaAlgiers, AlgeriaTaking people
- CLCC AnnabaAnnaba, AlgeriaTaking people
- CLCC BatnaBatna City, AlgeriaTaking people
- CHU- Hôpital Khelil AmraneBéjaïa, AlgeriaTaking people
- CAC-CHU Frantz FanonBlida, AlgeriaTaking people
- CHU Dr Abdesselam BenbadisConstantine, AlgeriaTaking people
- EH Didouche MouradConstantine, AlgeriaTaking people
- CAC El OUEDEl Oued, AlgeriaTaking people
- CAC-LaghouatLaghouat, AlgeriaTaking people
- CAC Oran EL HASSI- EMIR ABDELKADEROran, AlgeriaTaking people
- CHU Dr. Benaouda BenzerdjebOran, AlgeriaTaking people
- EHS 1er novembreOran, AlgeriaTaking people
- CAC- OuarglaOuargla, AlgeriaTaking people
- CAC-SétifSétif, AlgeriaTaking people
- CAC- Sidi Bel AbbèsSidi Bel Abbes, AlgeriaTaking people
- EPH- Sidi GhilesTipasa, AlgeriaTaking people
- CLCC Draâ Ben KheddaTizi Ouzou, AlgeriaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Société Algérienne de Formation et de Recherche en Oncologie
- Trial code
- NCT07161882
- Record updated
- 16 September 2025
- Original description
SAFRO 2202 ALG-Lung Cancer Registry is a prospective, multicenter, non-interventional observational study conducted across 21 public and university hospitals in Algeria. The objective is to characterize the epidemiological, clinical, pathological, molecular, and therapeutic features of patients diagnosed with lung cancer, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), and carcinoid tumors.Read full original descriptionShow less
Observational Study of the Epidemiological, Clinical, and Diagnostic Profile, Treatment Patterns, and Outcomes of Lung Cancer.
SAFRO 2202 ALG-Lung Cancer Registry is a prospective, multicenter, non-interventional observational study conducted across 21 public and university hospitals in Algeria. The objective is to characterize the epidemiological, clinical, pathological, molecular, and therapeutic features of patients diagnosed with lung cancer, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), and carcinoid tumors.
Eligible participants are adults aged 18 years or older, diagnosed at the time of inclusion or within the previous 12 months, and fully managed in oncology or pulmonology departments. Data are collected during routine clinical care and recorded in a secure electronic case report form (eCRF). No protocol-mandated interventions or study-specific visits are required.
The study plans to enroll approximately 1,500 patients per year over a 30-month period. Primary outcomes include demographic and clinical profiles, tumor histology, molecular markers, staging at diagnosis, and treatment strategies (surgery, radiotherapy, chemotherapy, targeted therapy, and immunotherapy). Secondary outcomes include treatment-related toxicities, objective response rate (ORR), progression-free survival (PFS), time to treatment discontinuation (TTD), and overall survival (OS).
The findings from this registry will provide real-world evidence to support national health planning, improve lung cancer management, and guide future clinical and public health initiatives in Algeria.
Inclusion: Age ≥ 18 years; Histologically confirmed diagnosis of lung cancer (NSCLC, SCLC, or carcinoid tumor); Diagnosed at the time of inclusion or within the 12 previous months; Fully managed (diagnosis, treatment, and follow-up) in an oncology or pulmonology department of one of the 21 participating public/university hospitals; Signed informed consent obtained.
Exclusion: Prior enrollment in this study; Participation in an interventional clinical trial.